{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:27:50Z","timestamp":1771331270460,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive and irreversible fibrosis of lung parenchyma that reduces lung function. This rare, incurable disease often is mistaken for an inflammatory condition. IPF typically manifests in older men and is associated with a history of smoking. Disease progression is rapid, with a 5-year survival rate of 20%. Treatment options include lung transplantation and medical therapies to reduce the steady decline in lung function. This article reviews the epidemiology, pathophysiology, presentation, diagnosis, and management of IPF.<\/jats:p>","DOI":"10.1097\/01.jaa.0000544299.00459.a4","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T22:22:05Z","timestamp":1533766925000},"page":"21-26","source":"Crossref","is-referenced-by-count":6,"title":["Recommendations for evaluating and managing idiopathic pulmonary fibrosis"],"prefix":"10.1097","volume":"31","author":[{"given":"Daniel M.","family":"Provencher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Jauregui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"6","key":"R1-20230817","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"R2-20230817","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"R3-20230817","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.healun.2015.12.030","article-title":"Post-transplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation","volume":"35","author":"Chauhan","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R4-20230817","first-page":"w14139","article-title":"Idiopathic pulmonary fibrosis: the turning point is now!","volume":"145","author":"Funke","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"R5-20230817","first-page":"89","article-title":"Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis","volume":"10","author":"Inomata","year":"2015","journal-title":"Core Evid"},{"issue":"4","key":"R6-20230817","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/aje\/152.4.307","article-title":"Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers","volume":"152","author":"Baumgartner","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"3","key":"R7-20230817","first-page":"259","article-title":"Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan","volume":"49","author":"Miyake","year":"2005","journal-title":"Ann Occup Hyg"},{"issue":"6","key":"R8-20230817","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1164\/ajrccm.158.6.9804105","article-title":"Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis","volume":"158","author":"Tobin","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"38","key":"R9-20230817","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.3748\/wjg.14.5880","article-title":"Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis","volume":"14","author":"Arase","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"12","key":"R10-20230817","doi-asserted-by":"crossref","first-page":"e27800","DOI":"10.1371\/journal.pone.0027800","article-title":"Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases","volume":"6","author":"Lasithiotaki","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"R11-20230817","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201312-2221PP","article-title":"Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis: an integral model","volume":"189","author":"Selman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"R12-20230817","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","article-title":"A common MUC5B promoter polymorphism and pulmonary fibrosis","volume":"364","author":"Seibold","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"R13-20230817","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1513\/pats.200601-005TK","article-title":"Classification and natural history of the idiopathic interstitial pneumonias","volume":"3","author":"Kim","year":"2006","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"R14-20230817","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1843.2009.01672.x","article-title":"Current clinical trials for the treatment of idiopathic pulmonary fibrosis","volume":"15","author":"Klingsberg","year":"2010","journal-title":"Respirology"},{"issue":"4","key":"R15-20230817","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2213-2600(14)70011-6","article-title":"Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"5","key":"R16-20230817","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"12","key":"R17-20230817","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.4187\/respcare.03180","article-title":"Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program","volume":"59","author":"Gaunaurd","year":"2014","journal-title":"Respir Care"},{"issue":"1","key":"R18-20230817","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12890-016-0253-x","article-title":"Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan","volume":"16","author":"Oda","year":"2016","journal-title":"BMC Pulm Med"},{"issue":"9779","key":"R19-20230817","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"R20-20230817","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"R21-20230817","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1378\/chest.14-2817","article-title":"Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis","volume":"148","author":"Lederer","year":"2015","journal-title":"Chest"},{"issue":"1","key":"R22-20230817","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"R23-20230817","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"R26-20230817","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"R27-20230817","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1183\/09031936.00198013","article-title":"Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis","volume":"45","author":"Ogura","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"R28-20230817","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0022-5223(03)00600-7","article-title":"Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis","volume":"126","author":"Thabut","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"R29-20230817","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/resp.12778","article-title":"Pharmacological management of IPF","volume":"21","author":"Borie","year":"2016","journal-title":"Respirology"},{"issue":"6","key":"R30-20230817","doi-asserted-by":"crossref","first-page":"e0127771","DOI":"10.1371\/journal.pone.0127771","article-title":"Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Donahoe","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"R31-20230817","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/resp.12343","article-title":"A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Chambers","year":"2014","journal-title":"Respirology"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01720610-201809000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T01:09:17Z","timestamp":1692320957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201809000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000544299.00459.a4","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}